Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Eirion Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : As part of the agreement, HTL will validate and operate botulinum manufacturing facility in US. Botulinum is the active ingredient in Eirion's lead product candidate ET-01, a topical neuromodulator being developed for Crow's Feet wrinkles and primary axi...
Product Name : ET-01
Product Type : Protein
Upfront Cash : Undisclosed
August 09, 2021
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Eirion Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement